Completed PHASE1 INTERVENTIONAL 2-arm NCT04236219

ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers (SAD)

A Phase I Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

Sponsor: Allena Pharmaceuticals

Conditions Hyperuricemia

Interventions ALLN-346 Placebo

Updated 6 times since 2020 Last updated: Jul 19, 2021 Started: Sep 2, 2020 Primary completion: Nov 6, 2020 Completion: Nov 6, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hyperuricemia and is currently completed. Allena Pharmaceuticals leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
Jan 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE1
Jul 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

Phase: PHASE1_PHASE2 → PHASE1

▶ Show 1 earlier version

Feb 2020 — Jul 2020 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Allena Pharmaceuticals

Data source: Allena Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States